

Clinical Trial Information

Title of the study	Title of the study	Evaluation of dose responsiveness for T-705a in the treatment of seasonal infection with influenza
	Sponsor	Toyama Chemical Co.,Ltd.
	Study type	interventional (drug)
	Summary	To evaluate the efficacy and safety of 2 doses of T-705a versus an active control, oseltamivir phosphate, in the treatment of seasonal infection with influenza.
Details of the study	Drug name	T-705a
	Disease or conditions	Influenza virus infection
	Classification code of the drug	625 (anti-virus agents)
	Dosage	Oral
	Objectives of the study	Treatment
	Study phase	phase 2
	Study design	Randomized, multicenter, double-blind study
	Inclusion/exclusion criteria	Inclusion criteria: <ul style="list-style-type: none"> • Male and female • Patients who show a positive reaction to influenza virus antigen using a test kit from nasal or pharyngeal swabs. • Patients with a temperature (axillary) of 38.0°C or more at the first visit • Patients with 2 or more of influenza-like symptoms
	Endpoint	The time to pyretolysis (Duration of fever)
	Study status	In practice
Study region	Japan	
Related information	Name	The journal of Antimicrobial Agents and Chemotherapy
	URL	http://journals.pasteur.ac.ir/AAC02/46(4)/977.pdf
	Content	In vitro and in vivo activities of T-705
	Name	The journal of Antimicrobial Agents and Chemotherapy
	URL	http://aac.asm.org/cgi/reprint/49/3/981
	Content	Mechanism of action of T-705
Contact information	Organization	Toyama Chemical Co.,Ltd.
	Division	Clinical research department Development planning group
	Contact fax number and e-mail address	FAX : 03-3342-5145 E-mail : clinicaltrial@toyama-chemical.co.jp

以上